PRP for Diminished Ovarian Reserve
(PRP4POA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).
Will I have to stop taking my current medications?
The trial requires that you stop taking Aspirin or Motrin for one week before treatment. If you are on anticoagulant or antiaggregant treatments, you may not be eligible to participate.
Is PRP therapy safe for humans?
How is PRP treatment different from other treatments for diminished ovarian reserve?
PRP treatment is unique because it involves injecting a concentrated portion of the patient's own blood (platelet-rich plasma) directly into the ovaries, which may help improve ovarian function and increase pregnancy chances. This approach is novel compared to traditional fertility treatments and carries a lower risk of disease transmission and allergic reactions since it uses the patient's own blood.12367
What data supports the effectiveness of this treatment for diminished ovarian reserve?
Research suggests that injecting platelet-rich plasma (PRP) into the ovaries may help improve ovarian function and increase the chances of pregnancy in women with low ovarian reserve. Studies have shown that PRP can positively impact markers of ovarian reserve, oocyte (egg) quality, and embryo yield, potentially leading to better outcomes in fertility treatments.12368
Who Is on the Research Team?
David H Barad, MD MS
Principal Investigator
Center for Human Reproduction
Are You a Good Fit for This Trial?
Women under 45 with poor ovarian reserve, who haven't taken Aspirin or Motrin for a week, want to get pregnant through IVF, have had fewer than 6 eggs from past treatments, and have specific hormone levels (FSH > 12 and AMH < 1.0). It's not for those over age 45 or with certain blood diseases, clotting disorders, cancer, infections like sepsis, or autoimmune conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP) for ovarian function improvement
Follow-up
Participants are monitored for safety and effectiveness after treatment, including embryo production and hormone levels
What Are the Treatments Tested in This Trial?
Interventions
- PPP - Platelet Poor Plasma
- PRP - Platelet Rich Plasma
PPP - Platelet Poor Plasma is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Center for Human Reproduction
Lead Sponsor